GBE1 and adult polyglucosan body disease: One of these hits, the FDA approved glycogen synthase inhibitor guaiacol, indeed demonstrated in vivo safety and partial efficacy in the Gbe knockin mouse model of APBD Gbeys/ys (Kakhlon et al, 2018).